The predictive value of the antioxidative function of HDL for cardiovascular disease and graft failure in renal transplant recipients

Leberkühne, Lynn J; Ebtehaj, Sanam; Dimova, Lidiya G.; Dikkers, Arne; Dullaart, Robin P. F.; Bakker, Stephan J. L.; Tietge, Uwe J. F.

doi:10.1016/j.atherosclerosis.2016.04.008

Cited by 12 publications

(19 citation statements)

References 32 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The primary endpoints consisted in CVD mortality, all-cause mortality and graft failure. As previously reported [21,22]. graft failure was defined as return to dialysis or re-transplantation.…”

Section: Methodsmentioning

confidence: 99%

Autoantibodies to Apolipoprotein A-1 as Independent Predictors of Cardiovascular Mortality in Renal Transplant Recipients

Anderson

Pagano

Virzi

et al. 2019

JCM

Self Cite

View full text Add to dashboard Cite

Renal transplant recipients (RTRs) are known to have a high cardio-vascular disease (CVD) burden only partly explained by traditional CVD risk factors. The aim of this paper was therefore to determine: i) the prognostic value of autoantibodies against apoA-1 (anti-apoA-1 IgG) for incidence of CVD mortality, all-cause mortality and graft failure in RTR. Four hundred and sixty two (462) prospectively included RTRs were followed for 7.0 years. Baseline anti-apoA-1 IgG were determined and associations with incidence of CVD mortality (n = 48), all-cause mortality (n = 92) and graft failure (n = 39) were tested. Kaplan–Meier analyses demonstrated significant associations between tertiles of anti-apoA-1 IgG and CVD mortality (log rank test: p = 0.048). Adjusted Cox regression analysis showed a 54% increase in risk for CVD mortality for each anti-apoA-1 IgG levels standard deviation increase (hazard ratio [HR]: 1.54, 95% Confidence Interval [95%CI]: 1.14–2.05, p = 0.005), and a 33% increase for all-cause mortality (HR: 1.33; 95%CI: 1.06–1.67, p = 0.01), independent of CVD risk factors, renal function and HDL function. The association with all-cause mortality disappeared after excluding cases of CVD specific mortality. The sensitivity, specificity, positive predictive value, and negative predictive value of anti-apoA-1 positivity for CVD mortality were 18.0%, 89.3%, 17.0%, and 90.0%, respectively. HDL functionality was not associated with anti-apoA-1 IgG levels. This prospective study demonstrates that in RTR, anti-apoA-1 IgG are independent predictors of CVD mortality and are not associated with HDL functionality.

show abstract

Section: Methodsmentioning

confidence: 99%

Autoantibodies to Apolipoprotein A-1 as Independent Predictors of Cardiovascular Mortality in Renal Transplant Recipients

Anderson

Pagano

Virzi

et al. 2019

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…57 Several primary and secondary prevention measures in the general population have led to a temporal decline in cardiovascular disease and mortality. [10][11][12]59 We also note that congestive heart failure, and not ischemic heart disease, is the most common cause of CVEs after kidney transplantation, with a crude incidence of 21.23 events per 1000 person-years. [10][11][12]59 We also note that congestive heart failure, and not ischemic heart disease, is the most common cause of CVEs after kidney transplantation, with a crude incidence of 21.23 events per 1000 person-years.…”

Section: Discussionmentioning

confidence: 73%

“…57,58 This is unlikely to occur in the KT recipient population, as mean recipient age at transplantation is rising, there is a high prevalence of cardiovascular disease with age in this population, and conventional therapeutic strategies are often ineffective. [10][11][12]59 We also note that congestive heart failure, and not ischemic heart disease, is the most common cause of CVEs after kidney transplantation, with a crude incidence of 21.23 events per 1000 person-years. A previous study has reported a higher incidence of de novo heart failure but a similar incidence of de novo ischemic heart disease among KT recipients when compared to the population-based cohorts from Framingham and Minnesota.…”

Section: Discussionmentioning

confidence: 73%

“…[10][11][12] Hence, there is a need to better understand the risk factors associated with CVEs in this specific population and to develop therapeutics tailored to prevent and treat these events. [10][11][12] Hence, there is a need to better understand the risk factors associated with CVEs in this specific population and to develop therapeutics tailored to prevent and treat these events.…”

mentioning

confidence: 99%

“…cardioprotective therapies might be ineffective in KT recipients. [10][11][12] Hence, there is a need to better understand the risk factors associated with CVEs in this specific population and to develop therapeutics tailored to prevent and treat these events.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Induction immunosuppression agents as risk factors for incident cardiovascular events and mortality after kidney transplantation

Sandal

Bae

McAdams‐DeMarco

et al. 2019

American Journal of Transplantation

View full text Add to dashboard Cite

Low T cell counts and acute rejection are associated with increased cardiovascular events (CVEs); T cell–depleting agents decrease both. Thus, we aimed to characterize the risk of CVEs by using an induction agent used in kidney transplant recipients. We conducted a secondary data analysis of patients who received a kidney transplant and used Medicare as their primary insurance from 1999 to 2010. Outcomes of interest were incident CVE, all‐cause mortality, CVE‐related mortality, and a composite outcome of mortality and CVE. Of 47 258 recipients, 29.3% received IL‐2 receptor antagonist (IL‐2RA), 33.3% received anti‐thymocyte globulin (ATG), 7.3% received alemtuzumab, and 30.0% received no induction. Compared with IL‐2RA, there was no difference in the risk of CVE in the ATG (adjusted hazard ratio [aHR] 0.98, 95% confidence interval [CI] 0.92‐1.05) and alemtuzumab group (aHR 1.01, 95% CI 0.89‐1.16), but slightly higher in the no induction group (aHR 1.06, 95% CI 1.00‐1.14). Acute rejection did not modify this association in the latter group but did increase CVE by 46% in the alemtuzumab group. There was no difference in the hazard of all‐cause or CVE‐related mortality. Only in the ATG group, a 7% lower hazard of the composite outcome of mortality and CVE was noted. Induction agents are not associated with incident CVE, although prospective trials are needed to determine a personalized approach to prevention.

show abstract

Vitamin E Serum Levels and the Challenge to Correct for Lipids: Accounting for the Usual Double Correction for Variance Shared by Total Cholesterol and Fasting Triglycerides Reveals New Insights into the Association with the One-Carbon Pathway

Minovíc

Sotomayor

Eggersdorfer

et al. 2019

Vitamin E in Human Health

View full text Add to dashboard Cite

The predictive value of the antioxidative function of HDL for cardiovascular disease and graft failure in renal transplant recipients

Abstract: This study demonstrates that the antioxidative function of HDL (i) does not predict cardiovascular or all-cause mortality in RTR, but (ii) conceivably contributes to the development of graft failure, however, not independent of baseline kidney function and inflammatory load.

Cited by 12 publications

References 32 publications

Autoantibodies to Apolipoprotein A-1 as Independent Predictors of Cardiovascular Mortality in Renal Transplant Recipients

Autoantibodies to Apolipoprotein A-1 as Independent Predictors of Cardiovascular Mortality in Renal Transplant Recipients

Induction immunosuppression agents as risk factors for incident cardiovascular events and mortality after kidney transplantation

Vitamin E Serum Levels and the Challenge to Correct for Lipids: Accounting for the Usual Double Correction for Variance Shared by Total Cholesterol and Fasting Triglycerides Reveals New Insights into the Association with the One-Carbon Pathway

Contact Info

Product

Resources

About